Warum fällt Synsorb wieder? - 500 Beiträge pro Seite

[Michael Tuerk]

Hallo, weiss jemand zufällig, warum Synsorb heute wieder fällt. Gab es schon das Ergebniss für Phase III. Was gab es gestern für News? Könnte mir das bitte jemand übersetzen?

Vielen Dank,
Michael Türk

[andi.b]

was is los bei synsorb?
kommen heute die langersehnten news???
der kurs sieht jedenfalls nicht danach aus!

[Montezuma]

Auf jeden Fall ist es verdammt ruhig. Ich nehme an, da ich ein Optimist bin, kommt die nächste ein Hammermeldung und zwar in Form der Zulassung von einem Medikament!

[Michael Tuerk]

Wo blieb heute die Meldung über die Zulassung des Medikaments? Wahr wohl nicht´s oder? Kommt Sie überhaupt noch?

Viele Grüße,

Michael Türk

[sliderman]

Na wer so dumm wäre bei geschlossener Börse results rauszugeben, den möchte ich mal sehen !
Außerdem solltes Du mitbekommen haben, daß die Ergebnisse nicht von Synsorb ausgewertet werden.

[Michael Tuerk]

Soll das also heissen, dass das noch einige Monate dann dauern kann? Warum schreibst du dann News über Zulassung am 3. bzw. 4 Juli wenn keines von beiden stimmt?

Viele Grüße,

Michael Türk

[sliderman]

Zuerst einmal habe ich nie was von Zulassung geschrieben !

Ob das so toll wäre, wenn die Unternehmen ihre eigenen Medikamente zulassen könnten.
Es ist aber richtig, daß die Ergebnisse der Phase III(PK) eigentlich schon Ende des II.Quartals vorliegen sollten.
So müssen wir uns noch ein bischen gedulden.
Wenn Du mehr Infos brauchst, lies Dir einfach die letzten 100 beiträge im YAHOO-Board (SYBB) durch.

Sliderman

[Michael Tuerk]

News bei Synsorb auf der Homepage. Könnte mir das Bitte jemand übersetzen?

Vielen Dank schon im Vorraus,

Michael Tuerk

[andi.b]

Thursday July 6, 7:17 am Eastern Time

Company Press Release

SYNSORB Biotech Inc. Announces Final Phase II Results for SYNSORB
CD(R) Study

CALGARY, Alberta--(BUSINESS WIRE)--July 6, 2000--SYNSORB (Nasdaq:SYBB - news; TSE:SYB. - news)

SYNSORB Biotech Inc. (``SYNSORB``) (TSE:SYB. - news; Nasdaq:SYBB - news), today announced that the Company has received the final SYNSORB Cd®
Phase II analysis, the primary endpoint for which is the rate of recurrence of Clostridium difficile associated disease (CDAD).

The results showed that 41.7% of patients on placebo experienced recurrence of CDAD after their initial episode, whereas only 21.9% of those receiving 16g per
day of SYNSORB Cd® experienced recurrence. This represents a relative risk reduction of 61%. This strong trend in favour of the drug confirms the Company`s
September 1999 decision to move aggressively into Phase III clinical trials.

``These final results confirm that the Phase II trial successfully met its objectives,`` said Dr. David Cox, President and CEO of SYNSORB. ``When we originally
designed the trial it was determined that a relative risk reduction of at least 50% would be considered successful, so we are pleased that in the final analysis the drug
showed 61% at the higher dose. The Phase III trials are well underway and we look forward to reporting on our continued progress.``

Patients enrolled in the Phase II trial had already suffered at least one occurrence of CDAD. All patients were treated with the antibiotic metronidazole (normal first
line treatment of CDAD) for the first 10 days, and were randomized to receive either a placebo, low dose (8 grams per day) or high dose (16 grams per day) of
SYNSORB Cd®, administered orally in powder form. Patients received SYNSORB Cd® from days 1 through 25 and were monitored for 67 days.

Of the 86 evaluable patients in the study, 41.7% of patients in the placebo group demonstrated recurrence (10 of 24), 36.7% on the 8g/day dose (11 of 30) and
21.9% on the 16g/day dose (7 of 32), P= 0.116 for 16g/day vs. placebo. The risk reduction for recurrence of the high dose relative to placebo was 61%. The
analysis also confirmed that there were no serious adverse events attributable to SYNSORB Cd®.

Results previously reported by the Company in September of 1999 were based on Phase II interim data available at that time. For the final Phase II data analysis
reported today, a stringent definition of recurrence was applied which required patients to be both clinically diagnosed with recurrence as well as having a
microbiological test documented to confirm it. Application of the rigorous definition of recurrence resulted in exclusion of a number of patients from the final analysis.
This reduced the number of patients available for statistical evaluation and led to changes in the rate of recurrence but still resulted in a strong trend in favour of the
drug. Future analyses planned for the SYNSORB Cd® Phase III trial protocol will utilize this more stringent definition and are aided by the availability of a rapid test
kit now used in confirming a diagnosis of recurrence.

The SYNSORB Cd® Phase III clinical trials are investigating the effects of the 16g dose versus a 24g per day dose, compared with placebo, at 120 sites.
Enrollment is on target for this point in the trials and discussions continue with potential marketing and distribution partners for SYNSORB Cd® in key jurisdictions
such as the US and Europe.

SYNSORB is a Canadian-based pharmaceutical company dedicated to drug development and manufacturing. The Company`s two Phase III products have been
granted ``Fast Track`` designation by the FDA and are both based on SYNSORB`s proprietary carbohydrate chemistry platform technology. SYNSORB Pk® is
designed to prevent the progression to Hemolytic Uremic Syndrome (HUS) in children who have contracted verotoxigenic E. coli (VTEC) infections, including E.
coli O157:H7. SYNSORB Cd® is a potential treatment for recurrent C. difficile antibiotic associated diarrhea (CDAD), a common hospital acquired infection.
SYNSORB has built a cGMP-compliant manufacturing facility that has the capacity to meet or exceed the expected global demand for the Company`s products. A
pipeline of future products is accessible through SYNSORB`s carbohybrid program.

Shares of SYNSORB Biotech Inc. trade on the Toronto Stock Exchange in Canada (symbol ``SYB``) and on NASDAQ in the United States (ticker ``SYBB``).

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company`s
control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations
implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in
the Company`s registration statement on Form 20 F filed with the Securities and Exchange Commission.

Contact:

SYNSORB Biotech Inc.
Cindy Gray, Investor Relations, 403/270-1315
Fax: [phone]
E-mail: [e-mail]
Website: www.synsorb.com
or
The Equicom Group
Jason Hogan, Investor Relations, 416/815-0700 ex222
Fax: [phone]
E-mail: [e-mail]
or
SYNSORB Biotech Inc.
Mr. Doug Froom, Vice President Business Development,
403/283-5900
Fax: [phone]
E-mail: [e-mail]
For product licensing inquiries